NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW
NewAmsterdam Pharma Company N.V. stock price today
$13.473
-0.99
-6.89%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
NewAmsterdam Pharma Company N.V. stock price monthly change
+43.27%
month
NewAmsterdam Pharma Company N.V. stock price quarterly change
+43.27%
quarter
NewAmsterdam Pharma Company N.V. stock price yearly change
+385.49%
year
NewAmsterdam Pharma Company N.V. key metrics
Market Cap | 2.58B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.88 |
Revenue | 109.29M |
EBITDA | -111.18M |
Income | -155.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -101.73% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNewAmsterdam Pharma Company N.V. stock price history
NewAmsterdam Pharma Company N.V. stock forecast
NewAmsterdam Pharma Company N.V. financial statements
| Dec 2022 | 97.5M | 20.36M | 20.88% |
|---|---|---|---|
| Mar 2023 | 8.62M | -42.01M | -486.94% |
| Jun 2023 | 1.76M | -39.59M | -2246.8% |
| Mar 2024 | 1.40M | -93.76M | -6692.86% |
| Jun 2023 | 471098000 | 48.83M | 10.37% |
|---|---|---|---|
| Sep 2023 | 0 | 0 | |
| Dec 2023 | 347097000 | 58.70M | 16.91% |
| Mar 2024 | 452699721 | 71.04M | 15.69% |
| Dec 2022 | 26.84M | 715K | 375.17M |
|---|---|---|---|
| Mar 2023 | -31.86M | -7K | 2.39M |
| Jun 2023 | -36.45M | 5.62M | 6.32M |
| Mar 2024 | -54.60M | -385K | 198.18M |
NewAmsterdam Pharma Company N.V. alternative data
| Aug 2023 | 8 |
|---|---|
| Sep 2023 | 8 |
| Oct 2023 | 8 |
| Nov 2023 | 8 |
| Dec 2023 | 8 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 29 |
| Apr 2024 | 29 |
| May 2024 | 29 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
NewAmsterdam Pharma Company N.V. other data
-
What's the price of NewAmsterdam Pharma Company N.V. stock today?
One share of NewAmsterdam Pharma Company N.V. stock can currently be purchased for approximately $13.47.
-
When is NewAmsterdam Pharma Company N.V.'s next earnings date?
Unfortunately, NewAmsterdam Pharma Company N.V.'s (NAMSW) next earnings date is currently unknown.
-
Does NewAmsterdam Pharma Company N.V. pay dividends?
No, NewAmsterdam Pharma Company N.V. does not pay dividends.
-
How much money does NewAmsterdam Pharma Company N.V. make?
NewAmsterdam Pharma Company N.V. has a market capitalization of 2.58B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 86.91% to 12.76M US dollars.
-
What is NewAmsterdam Pharma Company N.V.'s stock symbol?
NewAmsterdam Pharma Company N.V. is traded on the NASDAQ under the ticker symbol "NAMSW".
-
What is NewAmsterdam Pharma Company N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NewAmsterdam Pharma Company N.V.?
Shares of NewAmsterdam Pharma Company N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does NewAmsterdam Pharma Company N.V. have?
As Jul 2024, NewAmsterdam Pharma Company N.V. employs 40 workers, which is 38% more then previous quarter.
-
When NewAmsterdam Pharma Company N.V. went public?
NewAmsterdam Pharma Company N.V. is publicly traded company for more then 4 years since IPO on 10 Feb 2021.
-
What is NewAmsterdam Pharma Company N.V.'s official website?
The official website for NewAmsterdam Pharma Company N.V. is newamsterdampharma.com.
-
How can i contact NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. can be reached via phone at +31 35 206 2971.
NewAmsterdam Pharma Company N.V. company profile:
NewAmsterdam Pharma Company N.V.
newamsterdampharma.comExchange:
NASDAQ
Full time employees:
62
Industry:
Biotechnology
Sector:
Healthcare
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Gooimeer 2-35
Naarden, 1411 DC
Naarden, 1411 DC
CIK: 0001936258
ISIN: NL00150012K9
:
